Logo

Compugen to Collaborate with Merck Serono to Develop Peptide for Inflammatory Diseases

Nov 26, 2008
NEW YORK (GenomeWeb News) – Compugen will collaborate with Merck to develop a peptide that, based on recent in vitro and in vivo studies, potentially could be used in the treatment of inflammatory diseases and other indications.
 
The agreement covers additional research that Compugen will conduct on the CGEN-855 peptide, and gives Merck Serono an option to license it exclusively for worldwide development and commercialization.
 
Compugen said it discovered the peptide using its GPCR Peptide Ligands Discovery Platform. The Tel Aviv, Israel-based company also said that it currently has other peptide candidates “moving forward” in collaborations with Merck Serono, including ones that may be relevant to cancer, inflammation, metabolism, and cardiovascular disease.
 
Financial terms of the agreement were not released.

Filed under

Informatics
Breaking News
The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.